Saroglitazar

Drug Profile

Saroglitazar

Alternative Names: Lipaglyn; ZY-H1

Latest Information Update: 24 Nov 2016

Price : $50

At a glance

  • Originator Zydus-Cadila
  • Developer Zydus Cadila
  • Class Antihyperglycaemics; Antihyperlipidaemics; Small molecules
  • Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists; Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Dyslipidaemias; Hypertriglyceridaemia
  • Phase III Lipodystrophy; Non-alcoholic steatohepatitis; Type 2 diabetes mellitus
  • Clinical Phase Unknown Non-alcoholic fatty liver disease

Most Recent Events

  • 31 Oct 2016 Zydus initiates phase II trial for Non-alcoholic steatohepatitis in USA prior to October 2016
  • 11 Jun 2016 Clinical trials in Non-alcoholic fatty liver disease in India (PO) before June 2016
  • 11 Jun 2016 Preclinical trials in Type-2 diabetes mellitus (Combination therapy) in India (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top